Clinical study of 20 cases of refractory Mycobacterium avium complex pulmonary disease treated with amikacin liposomal inhalation suspension

被引：0
|
作者：
Kaneko, Taichi [1 ]
Hagiwara, Eri [1 ]
Okuda, Ryo [1 ]
Ogura, Takashi [1 ]
机构：
[1] Kanagawa Cardiovasc & Resp Ctr, Dept Resp Med, Yokohama, Kanagawa, Japan
来源：
RESPIROLOGY | 2024年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
AO13-003
引用
收藏
页码：48 / 49
页数：2
相关论文
共 50 条
  • [41] RELATIONSHIP BETWEEN IN VITRO CLARITHROMYCIN SUSCEPTIBILITY AND SPUTUM CULTURE CONVERSION WITH ADD-ON AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT OF REFRACTORY MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE
    Griffith, David
    Eagle, Gina
    Wallace, Richard
    Brown-Elliott, Barbara
    Van Ingen, Jakko
    Pennings, Lian
    Berry, Brooke
    Pandey, Sushil
    Coulter, Christopher
    Syrmis, Melanie
    Morimoto, Kozo
    Hasegawa, Naoki
    CHEST, 2018, 154 (04) : 109A - 110A
  • [42] The treatment outcomes of cavitary Mycobacterium avium complex pulmonary disease according to the use of amikacin or streptomycin
    Kim, Seong Min
    Shim, Tae Sun
    Jo, Kyung-Wook
    RESPIROLOGY, 2023, 28 : 204 - 204
  • [43] AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) ADDED TO COMBINATION REGIMEN ON RECURRENCE IN NEWLY DIAGNOSED OR RECURRENT MYCOBACTERIUM AVIUM COMPLEX (MAC): THE ARISE STUDY
    van Ingen, Jakko
    Terschlusen, Eva
    Yuen, Dayton
    May, Daniel
    Nevoret, Marie-Laure
    Ciesielska, Monika
    Stein, Daniel
    Mange, Kevin
    CHEST, 2024, 166 (04) : 995A - 996A
  • [44] Challenges in achieving the guideline-recommended amikacin level for Mycobacterium avium complex pulmonary disease
    Akutsu, Takuya
    Tone, Kazuya
    Hasegawa, Airi
    Kitayama, Takaaki
    Inaki, Shunsuke
    Gochi, Mina
    Takagi, Masamichi
    Araya, Jun
    JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES, 2025, 39
  • [45] Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use
    Kim, Seong Min
    Chong, Yong Pil
    Lee, Hyun Joo
    Shim, Tae Sun
    Jo, Kyung-Wook
    MICROBIOLOGY SPECTRUM, 2023, 11 (03)
  • [46] Randomized Phase 3 Trial of Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC) in Adult Patients
    Griffith, D. E.
    Eagle, G.
    Thomson, R. M.
    Aksamit, T. R.
    Hasegawa, N.
    Morimoto, K.
    Addrizzo-Harris, D. J.
    O'Donnell, A. E.
    Marras, T. K.
    Flume, P. A.
    Loebinger, M. R.
    Morgan, L. C.
    Castellotti, P. F.
    Hill, A. T.
    Ruoss, S. J.
    Yim, J. J.
    Ringshausen, F. C.
    Field, S. K.
    Nezamis, J.
    Winthrop, K. L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [47] Clinical features of eleven cases of Mycobacterium avium-intracellulare complex pulmonary disease associated with pneumoconiosis
    Fujita, J
    Kishimoto, T
    Ohtsuki, Y
    Shigeto, E
    Ohnishi, T
    Shiode, M
    Yamaji, Y
    Suemitsu, I
    Yamadori, I
    Bandoh, S
    Nishimura, K
    Matsushima, T
    Ishida, T
    RESPIRATORY MEDICINE, 2004, 98 (08) : 721 - 725
  • [48] Help for the diagnosis of some, but not all, cases of Mycobacterium avium -: Complex pulmonary disease
    Teirstein, Alvin S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (07) : 677 - 679
  • [49] Clinical outcomes in Mycobacterium xenopi versus Mycobacterium avium complex pulmonary disease: A retrospective matched cohort study
    Zaheen, Ahmad
    Hirama, Takashi
    Mehrabi, Matty
    Brode, Sarah K.
    Marras, Theodore K.
    RESPIRATORY MEDICINE, 2020, 167
  • [50] Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study
    Zweijpfenning, Sanne M. H.
    Kops, Stephan E. P.
    Boeree, Martin J.
    Kuipers, Saskia
    van Ingen, Jakko
    Hoefsloot, Wouter
    Magis-Escurra, Cecile
    ERJ OPEN RESEARCH, 2021, 7 (04)
12345